However, in CF, physical activity assessment is often not a routine clinical measure; with the transformational care and management of this disease and the latest cystic fibrosis transmembrane conductance regulator modulator drug therapies, the increased functional capability of this population warrants further investigation. This evidence concerns the gene CFTR and cystic fibrosis.